{
    "Trade/Device Name(s)": [
        "Access Intrinsic Factor Ab"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240800",
    "Predicate Device Reference 510(k) Number(s)": [
        "K033603"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LIG"
    ],
    "Summary Letter Date": "May 3, 2024",
    "Summary Letter Received Date": "March 25, 2024",
    "Submission Date": "May 2, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1810"
    ],
    "Regulation Name(s)": [
        "Vitamin B12 test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Intrinsic factor antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle immunoassay"
    ],
    "Methodologies": [
        "Competitive binding immunoenzymatic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Access Intrinsic Factor Ab chemiluminescent immunoassay for detection of intrinsic factor antibodies to aid in diagnosis of pernicious anemia.",
    "Indications for Use Summary": "For in vitro diagnostic use as an aid in the diagnosis of pernicious anemia by detecting intrinsic factor antibody in human serum and plasma.",
    "fda_folder": "Clinical Chemistry"
}